New Delhi [India]: Serum Institute of India will export 10 lakh Covishield doses each to Nepal, Myanmar and Bangladesh, to help them fight against the pandemic, sources said.
The move by the Pune-based Serum Institute — the Indian manufacturer of the AstraZeneca-Oxford vaccine — will fasten the vaccination in the respective countries. So far, Serum Institute of India (SII) has supplied nearly 78 crore doses of its COVID-19 vaccine Covishield and its target is to supply almost 21.50 crore doses in the month of October, informed the sources to ANI on Friday.
Earlier, ANI reported on Friday, that the Centre targets to procure 27-28 crore vaccines this month and is expected to achieve 100 crore vaccinations before mid of October.
“The target of achieving this many doses will be from Serum Institute of India (SII) Covishield and Bharat Biotech’s Covid-19 vaccine Covaxin. India has procured more than 25 crores in the month of September,” informed the sources.
Must Read
- Serum Institute of India to start Covishield supply to COVAX…
- MoS Health visits Serum Institute of India, conveys…
- Serum Institute of India resumes exports of COVID-19 vaccine…
- Serum Institute working to develop COVID vaccine booster…
- Novavax, Serum Institute file for emergency use…
- Bombay HC issues notice to Central govt, Bill Gates and…
- Singapore to allow travelers from Bangladesh, India,…
- US to send delegation to Southeast Asia to discuss Myanmar…
- US to donate 100,620 more COVID-19 doses to Nepal
- Nepal receives 19,65,600 doses of Moderna vaccine under…